$26.90 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest


About Transmedics

Transmedics group, Inc. is a commercial-stage medical technology company. It is focused on developing organ transplant therapy for end-stage organ failure patients across multiple disease states. The Company has designed and developed organ care system (OCS) a portable organ perfusion, optimization and monitoring system that utilizes customized technology to replicate near-physiologic conditions for donor organs outside of the human body. It has developed three OCS products, one for each of lung, heart and liver transplantations. Its OCS clinical programs include OCS Lung INSPIRE Trial, OCS Lung Expand Trial, OCs Heart EXPAND and PROCEED II Trials. Its organ care system (OCS) technology platform to perfuse donor organs with warm, oxygenated, nutrient-enriched blood, while maintaining the organs in a living, functioning state; the lung is breathing, the heart is beating and the liver is producing bile. It is also focused on developing additional OCS products for kidney transplantation.

Stock Analysis

last close $26.9
1-mo return -8.6%
3-mo return -13.5%
avg daily vol. 212.36T
52-week high 49.5
52-week low 11.51
market cap. $735M
forward pe -
annual div. -
roe -29.6%
ltg forecast -
dividend yield -
annual rev. $30M
inst own. 70.5%

Subscribe now for daily local and international financial news